Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Majed Khraishi, Jelena Ivanovic, Yvonne Zhang, Brad Millson, Marie-Josee Brabant, John Woolcott, Heather Jones & Cinzia Curiale. (2019) Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study . Current Medical Research and Opinion 35:11, pages 2025-2033.
Read now
Read now
Ning Wu, Sharvari Bhurke, Neel Shah & David J Harrison. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. ClinicoEconomics and Outcomes Research 7, pages 257-266.
Read now
Read now
Vasilis Fragoulakis, Elli Vitsou, Ana Cristina Hernandez & Nikolaos Maniadakis. (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. ClinicoEconomics and Outcomes Research 7, pages 85-93.
Read now
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Read now
Julio Martinez-Cutillas, Carme Alerany-Pardo, Joaquín Borrás-Blasco, Antonio Broto-Sumalla, Amparo Burgos-SanJosé, Consuelo Climent-Bolta, Vicente Escudero-Vilaplana, María Anunciación Fernández-Fuente, Mónica Ferrit-Martin, Pilar Gómez-Germá, José Manuel Martínez-Sesmero, Jesús Mayorga-Pérez, Belén Menchén-Viso, Javier Merino-Alonso, Josefa Polache-Vengud & Amelia Sánchez-Guerrero. (2015) The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 851-858.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Amie T. Joyce, Shravanthi R. Gandra, Kathleen M. Fox, Timothy W. Smith & Michael W. Pill. (2014) National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. Journal of Medical Economics 17:1, pages 1-10.
Read now
Read now
Maxine D. Fisher, Crystal Watson, Kathleen M. Fox, Yen-Wen Chen & Shravanthi R. Gandra. (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion 29:5, pages 561-568.
Read now
Read now
Machaon M.K. Bonafede, Shravanthi R. Gandra, Kathleen M. Fox & Kathleen L. Wilson. (2012) Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Journal of Medical Economics 15:4, pages 635-643.
Read now
Read now
V.F. Schabert, B. Bruce, C.F. Ferrufino, D.R. Globe, D.J. Harrison, B. Lingala & J.F. Fries. (2012) Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Current Medical Research and Opinion 28:4, pages 569-580.
Read now
Read now
Articles from other publishers (11)
Francois Nantel, Juejing Ling, Meagan Rachich, Odalis Asin-Milan, Brad Millson, Shane Golden, Huijuan Yang, Purva Barot & Allen J. Lehman. (2022) Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada. Rheumatology and Therapy 9:5, pages 1399-1420.
Crossref
Crossref
Carter Thorne, Gilles Boire, Andrew Chow, Kirsten Garces, Fang Liu, Melanie Poulin-Costello, Valery Walker & Boulos Haraoui. (2017) Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. The Open Rheumatology Journal 11:1, pages 123-135.
Crossref
Crossref
Sergio Schwartzman, Yunfeng Li, Huanxue Zhou & Jacqueline B. Palmer. (2017) Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clinical Rheumatology 36:7, pages 1579-1588.
Crossref
Crossref
I.Y.K. Iskandar, D.M. Ashcroft, R.B. Warren, I. Evans, K. McElhone, C.M. Owen, A.D. Burden, C.H. Smith, N.J. Reynolds & C.E.M. Griffiths. (2017) Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 176:5, pages 1297-1307.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Crossref
Sarah Neubauer, Mary Cifaldi, Thomas Mittendorf, Arijit Ganguli, Malte Wolff & Jan Zeidler. (2014) Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Economics Review 4:1.
Crossref
Crossref
Ning Wu, Yuan-Chi (Daisy) Lee, Neel Shah & David J. Harrison. (2014) Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study. Clinical Therapeutics 36:8, pages 1231-1241.e3.
Crossref
Crossref
Steven W. Blume, Kathleen M. Fox, George Joseph, Chien-Chia Chuang, Jessy Thomas & Shravanthi R. Gandra. (2013) Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting. Advances in Therapy 30:5, pages 517-527.
Crossref
Crossref
Machaon M. K. Bonafede, Shravanthi R. Gandra, Crystal Watson, Nicole Princic & Kathleen M. Fox. (2012) Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis. Advances in Therapy 29:3, pages 234-248.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Rheumatology 23:3, pages 317-324.
Crossref
Crossref